Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05858645
PHASE4

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2023-10-01

Completion Date

2026-06

Last Updated

2024-06-27

Healthy Volunteers

No

Interventions

DRUG

deucravacitinib

Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Locations (1)

University of California, San Francisco

San Francisco, California, United States